A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Latest Information Update: 19 Aug 2024
At a glance
- Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary) ; Talquetamab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Acronyms MonumenTAL-2
- Sponsors Janssen Research & Development
- 14 Aug 2024 Planned End Date changed from 29 Sep 2025 to 17 Jul 2025.
- 14 Aug 2024 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2024 Planned End Date changed from 1 Oct 2025 to 29 Sep 2025.